HeraMED Limited announced that it has signed an exclusive distribution agreement with Advanced Pregnancy Solutions Pty Ltd. HeraCARE is HMD's fully integrated in-home holistic pregnancy management solution specifically designed to improve prenatal and postnatal care by empowering expectant mothers and their support system to become engaged in a collaborative process focused on managing the medical, social and mental aspects of maternity care. As announced on the March 2, 2020, HeraCARE has completed all beta stage testing and is fully functional and poised to commence pilot projects. The HeraCARE service is offered through health care providers, insurers and employers to their pregnant audience to achieve the triple aim: Cost reduction, Better medical outcomes, Increased user (Professionals and expecting mothers) satisfaction. Under the terms of the agreement, APS will leverage its and MedTech Edge's extensive network of industry contacts to establish relationships with a broad network of top-tier medical institutions and healthcare pioneers to amplify. HeraCARE's exposure as an innovative telehealth solution and secure pilot projects ahead of signing commercial agreements. The key terms of the agreement are: An initial two year term; Exclusive distributor for Australia and New Zealand for HMD's medical device used for home pregnancy monitoring (Device) and its associated proprietary hybrid maternity care platform, HeraCARE (HeraCare); HeraMED will pay to APS: Marketing and setup fee of AUD 11,500 + gst; and Monthly business development, consulting and management fee of AUD 3,850 + gst for 6 months to support the promotion of HeraCARE. HeraMED and APS will no later than four months from the execution of this agreement, jointly develop and agree on a business model based on monthly subscription. Such business model will be based on a revenue sharing between HeraMED and APS. Certain annual minimum targets relating to the Device and HeraCARE have been set by the parties.